GlaxoSmithKline begins shipping 2017-18 influenza vaccines for U.S. market
GSK announced it has begun shipping quadrivalent vaccine doses to U.S. healthcare providers, following licensing and lot-release approval from the U.S. FDA Center for Biologics Evaluation and Research. Three different options of the four-strain vaccines will be available to customers. FLULAVAL QUADRIVALENT comes in a 5mL, multidose vial containing 10 doses (0.5mL each) and a 0.5mL, single-dose, prefilled syringe, while FLUARIX QUADRIVALENT comes in a 0.5mL, single-dose, prefilled syringe. GSK expects to supply up to 40M doses across both vaccines for the US market in the 2017-18 season. GSK is committed to broad protection against influenza so one hundred percent of GSK supply is quadrivalent.